Skip to content

The Preliminary Clinical Trial of Treating Diabetic Nephropathy by hUCT-MSC

The Preliminary Clinical Trial of Treating Diabetic Nephropathy by hUCT-MSC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17011065
Enrollment
Unknown
Registered
2017-04-05
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Interventions

mesenchymal stem cells group:mesenchymal stem cells

Sponsors

Nephrology Department of The First Affiliated Hospital of The Chinese People's Liberation Army Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Willing and able to provide written informed consent; 2. Male and female aged 18 to 60 years old; 3. One of the following conditions should be diagnosed as diabetic nephropathyA diagnosed as T2 diabetic nephropathy:(ADA guidelines fo diagnosis and treatment of diabetes in 2014) to be associated with diabetic retinopathy,albuminuria and renal damage, consistent with the clinical diagnosis of Diabetic Nephropathy Bdiabetic nephrosis after kidney puncture and biopsy pathology histology changes; 4. Ubjects received at least a antidiabetic drug and ACEI/ or ARB (RAS inhibitor) therapy for at least 3 months before the screening period; 5. HbA1c=12%; 6. Urine albumin to creatinine ratio (UACR) =1000 mg/g and ?5000mg/g (in a spot morning urine collection); 7. Estimated GFR (eGFR) 25-60 ml/min/1.73 m^2; 8. Ability to follow research or follow up procedure.

Exclusion criteria

Exclusion criteria: 1. A recent birth plan for pregnant or lactating women; 2. Inability to understand the potential risks and benefits of the study and to follow up on the request; 3. No capacity for civil conduct; 4. History of drug or alcohol abuse; 5. Allergic to any ingredient used in cell culture; 6. Active infection; 7. Combined with other non diabetic nephropathy, immune disease, connective tissue disease, amyloidosis, and immunosuppressive therapy; 8. There are any more complex medical problems that may interfere with research behavior or lead to increased risk, such as cancer, blood disease, heart disease, liver disease, AIDS, viral hepatitis, etc.

Design outcomes

Primary

MeasureTime frame
urinary albumin to creatinine ratio;serum creatinine, sCr;stimated glomerular filtration rate (eGFR);

Secondary

MeasureTime frame
24h quantitative testing for urine protein;remission rate;recurrence rate;adverse event;

Countries

China

Contacts

Public ContactBingbing Shen

The First Affiliated Hospital of The Chinese People's Liberation Army Third Military Medical University

bingbingshen2291@sina.com+86 18696550155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026